

Hong Chang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8668063/publications.pdf>

Version: 2024-02-01

160
papers

5,345
citations

61984

43
h-index

98798

67
g-index

161
all docs

161
docs citations

161
times ranked

6137
citing authors

#	ARTICLE	IF	CITATIONS
1	Coexistence of multiple myeloma and perivascular endothelial cell tumor. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 42-43.	1.3	0
2	Hemophagocytosis arising during disease progression of chronic myelomonocytic leukemia. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 25-26.	1.3	1
3	Megakaryocytic emperipolesis in a therapy-related acute mixed phenotypic leukemia. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 694-695.	1.3	0
4	Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma. <i>Cancers</i> , 2022, 14, 1592.	3.7	8
5	NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1. <i>Leukemia Research</i> , 2022, 118, 106869.	0.8	6
6	Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KITD816V and FLT3-ITD. <i>Leukemia</i> , 2021, 35, 282-285.	7.2	1
7	Laboratory practices for manual blood film review: Results of an IQMH patterns of practice survey. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 184-190.	1.3	6
8	Multiple Auer rods in a mixed-phenotype acute leukemia. <i>Blood</i> , 2021, 137, 1702-1702.	1.4	0
9	Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies. <i>Biomarker Research</i> , 2021, 9, 34.	6.8	10
10	Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML. <i>Blood</i> , 2021, 137, 2853-2853.	1.4	2
11	SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma. <i>Biomarker Research</i> , 2021, 9, 48.	6.8	8
12	Mixed phenotype acute leukaemia with predominant myeloid blasts and a small subset of B/myeloid blasts shares the same mutation profile. <i>British Journal of Haematology</i> , 2020, 188, e60-e63.	2.5	0
13	Prognostic relevance of CD123 expression in adult AML with normal karyotype. <i>British Journal of Haematology</i> , 2020, 188, 181-184.	2.5	13
14	Role of CD47 in Hematological Malignancies. <i>Journal of Hematology and Oncology</i> , 2020, 13, 96.	17.0	76
15	Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1995-2000.	2.0	2
16	Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome. <i>Human Pathology</i> , 2020, 104, 117-126.	2.0	8
17	Mixed phenotype acute leukemia with a predominant B/T and a small subset of myeloid lineage expression. <i>EJHaem</i> , 2020, 1, 402-403.	1.0	0
18	Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma. <i>Haematologica</i> , 2020, 105, 2813-2823.	3.5	38

#	ARTICLE	IF	CITATIONS
19	MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma. <i>Cancer Letters</i> , 2020, 480, 29-38.	7.2	12
20	Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells. <i>BMC Cancer</i> , 2019, 19, 975.	2.6	19
21	Overexpression of Mir-21-5p Induces Apoptosis and Cell Cycle Arrest By Down-Regulating SKP2 and Overcomes Bortezomib Resistance in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1823-1823.	1.4	2
22	Downregulation of MDM2 Leads to Anti-Proliferative Effects through Activation of p53-Associated Pathway Mediated By Both Dual Inhibitor MX69 and Mir-548c-3p in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4419-4419.	1.4	1
23	Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. <i>Journal of Hematology and Oncology</i> , 2018, 11, 46.	17.0	53
24	EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. <i>Biomarker Research</i> , 2018, 6, 34.	6.8	41
25	Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS. <i>Leukemia</i> , 2018, 32, 2471-2482.	7.2	63
26	Synchronous T lymphoblastic lymphoma and myeloid neoplasm with <i>PDGFRA</i> rearrangement. <i>International Journal of Laboratory Hematology</i> , 2017, 39, e28-e32.	1.3	3
27	Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 Abnormalities in B-Cell Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 215-219.	0.4	5
28	Expression of <i>CD</i> 4 is correlated with an unfavorable prognosis in wild-type <i>NPM</i> 1, <i>FLT</i> 3-ITD-negative cytogenetically normal adult acute myeloid leukemia. <i>International Journal of Laboratory Hematology</i> , 2017, 39, 429-437.	1.3	5
29	Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification. <i>Leukemia Research</i> , 2017, 61, 39-43.	0.8	2
30	Acute myeloid leukemia with mutated <i>NPM</i> 1 demonstrating multilineage dysplasia and marked thrombocytosis. <i>British Journal of Haematology</i> , 2017, 178, 350-350.	2.5	1
31	Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 121.	17.0	50
32	Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting <i>AURKA</i> in multiple myeloma. <i>Leukemia</i> , 2017, 31, 1123-1135.	7.2	61
33	Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 169.	17.0	55
34	<i>CD</i> 33, not early precursor T-cell phenotype, is associated with adverse outcome in adult T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 823-825.	2.5	11
35	High <i>IKZF1/3</i> protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide. <i>Journal of Hematology and Oncology</i> , 2016, 9, 123.	17.0	25
36	Extracorporeal photopheresis in solid organ transplant-associated acute graft-versus-host disease. <i>Transfusion</i> , 2016, 56, 962-969.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Marcks Peptide Inhibitor Displays Synergistic Cytotoxicity with Bortezomib in Drug Resistant Multiple Myeloma Cells but Enhances Autophagic Effect. <i>Blood</i> , 2016, 128, 2061-2061.	1.4	1
38	Role of micro-RNAs in drug resistance of multiple myeloma. <i>Oncotarget</i> , 2016, 7, 60723-60735.	1.8	37
39	miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. <i>Oncotarget</i> , 2016, 7, 7149-7160.	1.8	29
40	IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide. <i>Blood</i> , 2016, 128, 4506-4506.	1.4	0
41	Dutcher bodies in multiple myeloma are highly associated with translocation t(4;14) and IgA isotype. <i>British Journal of Haematology</i> , 2015, 171, 890-892.	2.5	4
42	miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 2399-2411.	7.0	106
43	Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway. <i>Scientific Reports</i> , 2015, 5, 9925.	3.3	25
44	PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53. <i>Cancer Biology and Therapy</i> , 2015, 16, 799-806.	3.4	22
45	Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. <i>Leukemia</i> , 2015, 29, 715-726.	7.2	60
46	Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. <i>British Journal of Cancer</i> , 2014, 110, 2224-2231.	6.4	31
47	Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 690-695.	2.0	21
48	Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment. <i>Biomarker Research</i> , 2014, 2, 10.	6.8	29
49	Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival. <i>Leukemia Research</i> , 2014, 38, 666-672.	0.8	1
50	Distinct characteristics and new prognostic scoring system for Chinese patients with Waldenström macroglobulinemia. <i>Chinese Medical Journal</i> , 2014, 127, 2327-31.	2.3	8
51	Targeting p53 by small molecules in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2013, 6, 23.	17.0	99
52	t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. <i>Leukemia Research</i> , 2013, 37, 1251-1257.	0.8	59
53	PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2331-2341.	4.1	82
54	CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia. <i>Leukemia Research</i> , 2013, 37, 122-128.	0.8	16

#	ARTICLE	IF	CITATIONS
55	CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. <i>Human Pathology</i> , 2013, 44, 2038-2046.	2.0	24
56	CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavourable acute myeloid leukemia. <i>Leukemia Research</i> , 2013, 37, 861.	0.8	6
57	Genomic aberrations in anaplastic multiple myeloma: High frequency of 1q21(CKS1B) amplifications. <i>Leukemia Research</i> , 2013, 37, 1726-1728.	0.8	19
58	Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. <i>Human Pathology</i> , 2013, 44, 55-61.	2.0	13
59	Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. <i>Oncotarget</i> , 2013, 4, 2186-2207.	1.8	145
60	Abnormalities Of FAM46C, AHCYL1, CDC14A and CDKN2C Genes Located At Chromosome 1p Detected By QM-FISH Identifies Deletion Of 1p32.3 Covered CDKN2C Is An Independent Adverse Prognostic Marker In Multiple Myeloma. <i>Blood</i> , 2013, 122, 3145-3145.	1.4	0
61	Small Molecule PRIMA-1 met Sensitizes Waldenstrom Macroglobulinemia Cells To Apoptosis and Displays Synergistic Cytotoxicity With Bortezomib. <i>Blood</i> , 2013, 122, 5143-5143.	1.4	0
62	Tumor Suppressor Microrna-29a/b and Microrna-34a Mediate Small Molecule PRIMA-1Met-Induced Aoptosis In Multiple Myeloma Cells By Targeting c-Myc. <i>Blood</i> , 2013, 122, 1919-1919.	1.4	0
63	Novel Targeting Of Phospho-Marcks Overcomes Drug Resistance and Induces Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma. <i>Blood</i> , 2013, 122, 282-282.	1.4	17
64	Genomic stratification of multiple myeloma treated with novel agents. <i>Leukemia and Lymphoma</i> , 2012, 53, 202-207.	1.3	13
65	p53 Nuclear Expression Correlates With Hemizygous TP53 Deletion and Predicts an Adverse Outcome for Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. <i>American Journal of Clinical Pathology</i> , 2012, 137, 208-212.	0.7	24
66	Mammary epithelial-restricted expression of activated c-src rescues the block to mammary gland morphogenesis due to the deletion of the C-terminus of Patched-1. <i>Developmental Biology</i> , 2012, 370, 187-197.	2.0	9
67	Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib. <i>Human Pathology</i> , 2012, 43, 858-864.	2.0	16
68	Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. <i>Cancer</i> , 2012, 118, 3962-3967.	4.1	47
69	Analysis of chromosome 12p deletion in plasma cell dyscrasias. <i>Leukemia Research</i> , 2012, 36, 32-36.	0.8	5
70	Targeting p53 by small molecule p53 activators in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2012, 5, .	17.0	1
71	Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy. <i>Blood</i> , 2012, 120, 1372-1372.	1.4	3
72	Targeting p53 via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma. <i>PLoS ONE</i> , 2012, 7, e30215.	2.5	68

#	ARTICLE	IF	CITATIONS
73	Mir-137 and Mir-197 within Chromosome 1p Minimal Deletion Region Regulate Apoptotic Activity in Multiple Myeloma by Targeting MCL 1. <i>Blood</i> , 2012, 120, 322-322.	1.4	0
74	Small Molecule MIRA-1 Induces p53-Independent Apoptosis in Multiple Myeloma Cells Through Activation of the p38 MAPK Signaling Pathway.. <i>Blood</i> , 2012, 120, 2937-2937.	1.4	1
75	Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. <i>Leukemia and Lymphoma</i> , 2011, 52, 1787-1794.	1.3	111
76	Genomic Aberrations and Survival of Patients with Light-Chain-Only Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1790-1795.	2.0	3
77	Suppressing miRNA-15a-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. <i>Journal of Hematology and Oncology</i> , 2011, 4, 37.	17.0	67
78	Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. <i>Leukemia Research</i> , 2011, 35, 95-98.	0.8	40
79	Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. <i>Leukemia Research</i> , 2011, 35, 492-498.	0.8	18
80	p53-Independent Anti-Myeloma Activity of Prima-1met. <i>Blood</i> , 2011, 118, 1826-1826.	1.4	0
81	MARCKS Confers Resistance to Velcade Through Skp2/p27-Mediated Pathway in Multiple Myeloma. <i>Blood</i> , 2011, 118, 985-985.	1.4	0
82	Targeting p53 Via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma. <i>Blood</i> , 2011, 118, 1836-1836.	1.4	0
83	CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. <i>Haematologica</i> , 2010, 95, 1542-1547.	3.5	31
84	RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 3041-3051.	4.1	45
85	1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2010, 45, 117-121.	2.4	71
86	Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (TP53)Deletion in Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2010, 133, 70-74.	0.7	24
87	Cytoplasmic Expression of Nucleophosmin Accurately Predicts Mutation in the Nucleophosmin Gene in Patients With Acute Myeloid Leukemia and Normal Karyotype. <i>American Journal of Clinical Pathology</i> , 2010, 133, 34-40.	0.7	34
88	MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. <i>Cancer Biology and Therapy</i> , 2010, 9, 936-944.	3.4	79
89	Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma. <i>Cancer Biology and Therapy</i> , 2010, 10, 567-578.	3.4	52
90	Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2010, 3, 13.	17.0	19

#	ARTICLE	IF	CITATIONS
91	Pharmacological activation of the p53 pathway in haematological malignancies. <i>Journal of Clinical Pathology</i> , 2010, 63, 204-209.	2.0	44
92	Activation of Erk by sonic hedgehog independent of canonical hedgehog signalling. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 1462-1471.	2.8	52
93	Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , 2010, 51, 2084-2091.	1.3	34
94	Small Molecule RITA Induces Apoptosis In Multiple Myeloma Cells through Activation of the p53 Pathway and Induction of ER-Stress response. <i>Blood</i> , 2010, 116, 790-790.	1.4	0
95	Prognostic Relevance of Genomic Aberrations In Light Chain Only Multiple Myeloma. <i>Blood</i> , 2010, 116, 4036-4036.	1.4	0
96	Loss of ALX4 expression in epithelial cells and adjacent stromal cells in breast cancer. <i>Journal of Clinical Pathology</i> , 2009, 62, 908-914.	2.0	9
97	Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. <i>Leukemia Research</i> , 2009, 33, 259-262.	0.8	67
98	p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 1357-1360.	0.8	51
99	Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter Study. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 36-38.	1.4	47
100	Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. <i>Blood</i> , 2009, 114, 522-525.	1.4	178
101	Molecular Mechanisms Mediating Antimyeloma Activity of An MDM2 Antagonist Nutlin.. <i>Blood</i> , 2009, 114, 3841-3841.	1.4	5
102	The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes. <i>Leukemia Research</i> , 2008, 32, 269-273.	0.8	24
103	Adult Precursor T-Lymphoblastic Leukemia/Lymphoma with Myeloid-Associated Antigen Expression Is Associated with a Lower Complete Remission Rate following Induction Chemotherapy. <i>Acta Haematologica</i> , 2008, 120, 5-10.	1.4	14
104	Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. <i>Journal of Clinical Pathology</i> , 2008, 61, 832-836.	2.0	21
105	Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.. <i>Blood</i> , 2008, 112, 1724-1724.	1.4	0
106	The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2008, 112, 1731-1731.	1.4	0
107	Aberrant expression of T-cell-associated markers CD4 and CD7 on B-cell chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2007, 82, 73-76.	4.1	14
108	CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. <i>Leukemia Research</i> , 2007, 31, 157-162.	0.8	54

#	ARTICLE	IF	CITATIONS
109	Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. <i>Leukemia Research</i> , 2007, 31, 779-782.	0.8	81
110	c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma. <i>Leukemia</i> , 2007, 21, 1572-1574.	7.2	17
111	Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. <i>Leukemia</i> , 2007, 21, 2358-2359.	7.2	18
112	Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. <i>British Journal of Haematology</i> , 2007, 138, 324-329.	2.5	43
113	Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2007, 139, 51-54.	2.5	52
114	Analysis of 6q deletion in Waldenstrom macroglobulinemia. <i>European Journal of Haematology</i> , 2007, 79, 244-247.	2.2	28
115	p53 Deletion Yields High Response Rates but Rapid Progression and Poor Overall Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 953-953.	1.4	1
116	Myeloid-Associated Antigen Expression Is an Adverse Factor for Complete Remission Following Induction Chemotherapy of Adult Precursor T-Lymphoblastic Leukemia/Lymphoma (T-ALL).. <i>Blood</i> , 2007, 110, 4228-4228.	1.4	0
117	The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. <i>Blood</i> , 2006, 107, 4039-4046.	1.4	139
118	Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. <i>British Journal of Haematology</i> , 2006, 134, 613-615.	2.5	32
119	Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2006, 135, 486-491.	2.5	85
120	Analysis of PTEN deletions and mutations in multiple myeloma. <i>Leukemia Research</i> , 2006, 30, 262-265.	0.8	72
121	Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2006, 47, 43-47.	1.3	45
122	Acute Myeloid Leukemia With Pseudo-Ch ²¹ diak-Higashi Anomaly Exhibits a Specific Immunophenotype With CD2 Expression. <i>American Journal of Clinical Pathology</i> , 2006, 125, 791-794.	0.7	7
123	Molecular Characterization of Chronic Lymphocytic Leukemia With Two Distinct Cell Populations. <i>American Journal of Clinical Pathology</i> , 2006, 126, 23-28.	0.7	13
124	Bortezomib Therapy Response Is Independent of Cytogenetic Abnormalities in Relapsed/Refractory Multiple Myeloma.. <i>Blood</i> , 2006, 108, 5081-5081.	1.4	2
125	Molecular Characterization of Chronic Lymphocytic Leukemia With Two Distinct Cell Populations: Evidence for Separate Clonal Origins. <i>American Journal of Clinical Pathology</i> , 2006, 126, 23-28.	0.7	5
126	Acute Myeloid Leukemia With Pseudo-Ch ²¹ diak-Higashi Anomaly Exhibits a Specific Immunophenotype With CD2 Expression. <i>American Journal of Clinical Pathology</i> , 2006, 125, 791-794.	0.7	1

#	ARTICLE	IF	CITATIONS
127	p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. <i>Blood</i> , 2005, 105, 358-360.	1.4	195
128	CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. <i>Blood</i> , 2005, 105, 2941-2948.	1.4	268
129	Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. <i>Blood</i> , 2005, 106, 353-355.	1.4	70
130	The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. <i>British Journal of Haematology</i> , 2005, 129, 539-541.	2.5	48
131	Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 36, 793-796.	2.4	60
132	t(11;14) does not predict long-term survival in myeloma. <i>Leukemia</i> , 2005, 19, 1078-1079.	7.2	11
133	Clonality analysis of cell lineages in acute myeloid leukemia with inversion 16. <i>Cancer Genetics and Cytogenetics</i> , 2005, 156, 175-178.	1.0	5
134	Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 2005, 156, 150-153.	1.0	36
135	Identification of cell lineages involved by t(15;17) in acute promyelocytic leukemia by combined fluorescence activated cell sorting and FISH. <i>Cancer Genetics and Cytogenetics</i> , 2005, 158, 43-48.	1.0	3
136	Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance. <i>Journal of Clinical Oncology</i> , 2005, 23, 7069-7073.	1.6	91
137	T-Cell Large Granular Lymphocytic Leukemia of Donor Origin Occurring After Allogeneic Bone Marrow Transplantation for B-Cell Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2005, 123, 196-199.	0.7	31
138	Prognostic Relevance of CD56 Expression in Patients with Multiple Myeloma Treated with High-Dose Melphalan-Based Chemotherapy and Autologous Stem Cell Transplant.. <i>Blood</i> , 2005, 106, 5086-5086.	1.4	0
139	T-cell large granular lymphocytic leukemia of donor origin occurring after allogeneic bone marrow transplantation for B-cell lymphoproliferative disorders. <i>American Journal of Clinical Pathology</i> , 2005, 123, 196-9.	0.7	9
140	Detection of Chromosome 13q Deletions and IgH Translocations in Patients with Multiple Myeloma by FISH: Comparison with Karyotype Analysis. <i>Leukemia and Lymphoma</i> , 2004, 45, 965-969.	1.3	31
141	Preclinical studies of fibroblast growth factor receptor ³ as a therapeutic target in multiple myeloma. <i>British Journal of Haematology</i> , 2004, 124, 595-603.	2.5	79
142	The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. <i>British Journal of Haematology</i> , 2004, 125, 64-68.	2.5	176
143	Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. <i>British Journal of Haematology</i> , 2004, 127, 280-284.	2.5	103
144	Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 cases. <i>Leukemia</i> , 2004, 18, 1160-1162.	7.2	46

#	ARTICLE	IF	CITATIONS
145	Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin. <i>Cancer Genetics and Cytogenetics</i> , 2004, 148, 44-48.	1.0	27
146	Interphase cytogenetic analysis of clonality in peripheral blood cells from a patient with Down syndrome and acute megakaryoblastic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2004, 148, 141-144.	1.0	1
147	Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence-activated cell sorting. <i>Cancer Genetics and Cytogenetics</i> , 2004, 152, 146-148.	1.0	12
148	Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2004, 28, 43-48.	0.8	116
149	Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. <i>Leukemia Research</i> , 2004, 28, 1007-1011.	0.8	139
150	Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia. <i>Leukemia Research</i> , 2004, 28, 1107-1111.	0.8	16
151	P53 Gene Deletion Detected by Fluorescence In Situ Hybridization Is an Adverse Prognostic Factor for Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 4884-4884.	1.4	0
152	Thalidomide +/â Corticosteroids for the Treatment of Multiple Myeloma Patients â 70 Years of Age.. <i>Blood</i> , 2004, 104, 4934-4934.	1.4	0
153	Allogeneic Red Blood Cell Transfusion Is an Independent Risk Factor for the Development of Postoperative Bacterial Infection. <i>Vox Sanguinis</i> , 2000, 78, 13-18.	1.5	106
154	Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusionâassociated graftâversusâhost disease from stored blood. <i>British Journal of Haematology</i> , 2000, 111, 146-156.	2.5	0
155	Allogeneic Red Blood Cell Transfusion Is an Independent Risk Factor for the Development of Postoperative Bacterial Infection. <i>Vox Sanguinis</i> , 2000, 78, 13-18.	1.5	45
156	Prospective audit of cytomegalovirus-negative blood product utilization in haematology/oncology patients. <i>Transfusion Medicine</i> , 1999, 9, 195-198.	1.1	2
157	The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. <i>Haemophilia</i> , 1999, 5, 247-252.	2.1	35
158	Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. <i>Leukemia</i> , 1999, 13, 105-109.	7.2	35
159	p53 Mutations, c-myc and bcl-2 Rearrangements in Human Non-Hodgkin's Lymphoma Cell Lines. <i>Leukemia and Lymphoma</i> , 1995, 19, 165-171.	1.3	40
160	Constitutive Production of the Interleukins IL-5 and IL-6 by the Lymphoma Cell Line OCI-Ly 17 Derived from a Patient with Malignant Lymphoma and Hypereosinophilia. <i>Leukemia and Lymphoma</i> , 1992, 8, 97-107.	1.3	17